Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
about
Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and TreatmentBevacizumab in Japanese patients with malignant glioma: from basic research to clinical trialTwo Patients With Brain Tumors Who Received Bevacizumab and Radiotherapy: Optic Neuropathy and Quality-of-Life IssuesRadiotherapy and "new" drugs-new side effects?Practical management of bevacizumab-related toxicities in glioblastomaTargeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanomaManagement of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Optic neuropathy in patients with glioblastoma receiving bevacizumab.Antiangiogenic therapy of brain tumors: the role of bevacizumab.The role of salvage reirradiation for malignant gliomas that progress on bevacizumab.Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report.New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab.Anti-angiogenesis therapies: their potential in cancer managementGoing past the data for temozolomide.Experimental approaches for the treatment of malignant gliomas.Antiangiogenic therapy for glioblastoma.Medical therapy of gliomas.Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approachesThe paradoxical effect of bevacizumab in the therapy of malignant gliomas.Temozolomide in malignant gliomaPhase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.Towards personalized therapy for patients with glioblastoma.Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinicDexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patientsCerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain.Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.Combining molecular targeted agents with radiation therapy for malignant gliomasPediatric developmental therapies: interesting new drugs now in early-stage clinical trials.Designer therapies for glioblastoma multiforme.Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis†.Anti-vascular endothelial growth factor therapy for malignant glioma.Angiogenesis as a therapeutic target in malignant gliomas.Antiangiogenic strategies for treatment of malignant gliomas.Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.
P2860
Q26785952-E3D6E3C5-81A3-49C7-8EC3-50A7D448B5BFQ26824777-A186BDB1-38C5-4C6A-94A1-5416A3F80E8AQ26853684-8A70A50B-9E4B-4394-AB67-BF6E0EACF01EQ26861498-0E154372-5772-4228-9103-6A099DB996D2Q27015852-C4388760-F20D-4A27-AF46-74EF0BE76B3FQ27326700-799BE3F5-B61A-4A1C-8277-1B42B8495ACEQ30417015-5D4FFDD7-2FE1-46C3-BF41-F04813A9A0F4Q30434029-B3D5BBAE-546E-48F6-A650-484B6FDF82F6Q30737224-F28E7CD5-20E6-4772-8CC9-F53FBC640CC6Q33511263-1D51303E-8987-4DDA-AF75-34EE43624C20Q33710092-0E9D506B-F8F9-45CC-BB69-6478AA15377AQ33956040-9F67316D-4D18-4DD9-B51C-372A2D885F6BQ33956056-2634131F-9B5D-4609-8149-6E6801246785Q34093083-30951D3D-05A5-4156-A109-9EDF6749702AQ34127138-411BF198-786D-47C9-9F17-167708D2FDC2Q34145245-107FB263-63E1-4E4A-BEB0-ECCCA3DF52E6Q34218761-9B9257C2-175B-400C-B63A-81D52B7651FEQ34515465-8232BEC5-AA9C-4193-A147-59086136F77FQ34536275-E69A20F8-7CF3-487A-BE56-F779C157E00EQ34623633-411A2EE4-AC4C-43C7-81FE-93A9949F14D4Q34679133-8913C1ED-931A-45A5-83A5-2ED9C1F302A0Q34764143-E48DB458-74E3-47F0-BD83-0EF9BFBBD881Q34978252-6705F310-6C2C-482E-9D4C-7F60A026BCD8Q35038016-32755356-6872-4BCA-8934-E4EB4607C698Q36235176-2B3FE6BA-93B9-4254-BB96-BF23D8AF7ACDQ36589758-617503E9-8091-4BD4-BFD6-5BBE1EEEE71BQ36787777-D23E4B2F-FA8A-4131-94E1-BD475215314AQ36828080-2AFC67B1-4F65-4348-8BA8-866F7A3D7FD8Q36860502-896987B4-D274-44B9-9BAF-5EF74333C4E1Q36982114-8A933326-2493-4ECD-8355-BE84E9B45219Q37099594-68224F26-F6C6-419D-9FA2-15DB5E9FAB0BQ37301320-9981C965-0DA2-46E4-B102-87603B630B12Q37319650-0830A92F-608A-41B7-9477-88623552429EQ37340643-05F097A5-B427-49EF-A089-C403DFFA3F9DQ37348479-C4CB179F-629E-4D62-AAC7-0FD384A02557Q37400326-D39B9AA8-EE76-4B06-AA49-E2A1CEEF6E25Q37434674-133D4618-6E0B-4EFB-9933-F4C0E14434CBQ37504362-86C2E0A4-B213-4B72-99A0-10C5C354FD09Q37533652-187E90A1-6695-4683-9741-61C54EA6A61EQ37564201-C43F19FA-E72D-40DF-BA1E-03368827AC80
P2860
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Phase II pilot study of bevaci ...... is of safety and tolerability.
@en
Phase II pilot study of bevaci ...... is of safety and tolerability.
@nl
type
label
Phase II pilot study of bevaci ...... is of safety and tolerability.
@en
Phase II pilot study of bevaci ...... is of safety and tolerability.
@nl
prefLabel
Phase II pilot study of bevaci ...... is of safety and tolerability.
@en
Phase II pilot study of bevaci ...... is of safety and tolerability.
@nl
P2093
P921
P1476
Phase II pilot study of bevaci ...... is of safety and tolerability.
@en
P2093
Albert Lai
Bruce McGibbon
Carrie Graham
Emese Filka
Linda M Liau
Marvin Bergsneider
Michael Selch
Paul Mischel
Phioanh Leia Nghiemphu
Tim Cloughesy
P304
P356
10.1016/J.IJROBP.2007.11.068
P407
P577
2008-03-20T00:00:00Z